Overview

Psoriasis is a chronic inflammatory dermatoses which include well demarcated scaly erythematous plaques on whole body including scalp role of methotrexate vs tofacitinib is compared in this study

Eligibility

Inclusion Criteria:

• Patients aged 18- 70 years of either gender.
• Only patients with Psoriasis Area and Severity Index (PASI) score of 10 or above, and/or Body Surface Area (BSA) involvement of 10% or more, will be included.
• Duration of plaque psoriasis for at least 6 months prior to the study.
• Psoriasis that has not shown adequate response to topical therapies

Exclusion Criteria:

• Individuals with other forms of psoriasis or other significant dermatological conditions that might interfere with the assessment of psoriasis.
• Participants currently receiving systemic corticosteroids, biologics, or any other immunosuppressive agents within 4 weeks prior to the start of the study will be excluded.
• Known hypersensitivity or contraindications to either methotrexate or tofacitinib.
• History of significant liver, kidney, hematologic/bleeding disorder, gastrointestinal/acid peptic disease, or immune system disorders.and any history of tuberculosis and malignancy.
• Pregnant or lactating women will not be eligible for the study.